This is a preview of subscription content, log in via an institution to check access.
Notes
The study was funded by an unrestricted grant from Bristol-Myers Squibb.
estimated from the perspective of the German healthcare payer
Reference
Beresniak A, et al. Cost-effectiveness simulation model of biologic strategies for treating to target rheumatoid arthritis in Germany. Clinical and Experimental Rheumatology : 4 Mar 2013. Available from: URL: http://dx.doi.org/6189
Rights and permissions
About this article
Cite this article
Switch to abatacept cost-effective option in RA. PharmacoEcon Outcomes News 676, 10 (2013). https://doi.org/10.1007/s40274-013-0334-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-013-0334-5